# Transplant - complications

## CMV disease

[**VICTOR**](https://www.ncbi.nlm.nih.gov/pubmed/17640310) (2007): ![](Logo_RCT.png){height=1.2em} - IV ganciclovir *vs.* oral valganciclovir for non-severe CMV disease.  Oral therapy was non-inferior.  

[**IMPACT**](https://www.ncbi.nlm.nih.gov/pubmed/21197713) (2010): ![](Logo_RCT.png){height=1.2em} - 100 *vs.* 200 days of valganciclovir prophylaxis in D+R- transplants.  Fewer cases of CMV disease by 2 years in the 200-day group.  


## CVS risk {#statin_Tx}

[**ALERT**](https://www.ncbi.nlm.nih.gov/pubmed/12814712) (2003): ![](Logo_RCT.png){height=1.2em} - fluvastatin *vs.* placebo in KTRs. Statin therapy for 5 yrs did not significantly reduce the primary end-point (MACE) but did reduce cardiac death and non-fatal MI.  

